Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.61 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.61 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.61 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.61 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.61 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.61 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945708 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL13431268 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL6021490 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL9410041 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL2763546 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL16668991 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL7055997 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL20241728 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| Methanesulfonamide SCHEMBL8296539 | 0.91 | MEN1 (0.83) | MEN1KMT2AKDM4EGRIA1GRIA2 | |
| SCHEMBL13431280 | 0.89 | KDM4E (0.80) | MEN1KMT2AKDM4EGRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | claimed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | claimed |
| EP-2139886-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2010-01-06 | — | — | EP | claimed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | claimed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | claimed |
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | NEURAXON, INC (CA) | 2008-09-04 | — | — | US | claimed |
| EP-1883451-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2008-02-06 | — | — | EP | claimed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | claimed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | claimed |
| EP-0580429-B1 | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence | LILLY CO ELI (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0580429-A1 | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence | ELI LILLY AND COMPANY (US) | 1994-01-26 | — | — | EP | claimed |
| US-5192751-A | Administering a decahydroisoquinoline derivative | ELI LILLY AND COMPANY (US) | 1993-03-09 | — | — | US | claimed |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3551182-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2025-03-19 | — | — | EP | disclosed |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPITAL | 2024-05-16 | — | — | US | disclosed |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | RHODE ISLAND HOSPITAL (US) | 2023-07-18 | — | — | US | disclosed |
| US-11478476-B2 | Use of buspirone metabolites | CONTERA PHARMA APS (DK) | 2022-10-25 | — | — | US | disclosed |
| US-11147799-B2 | Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain | Keppel Hesselink, Jan Marius (NL) | 2021-10-19 | — | — | US | disclosed |
| US-10894069-B2 | Topical antiviral formulations and methods of using the same | MCELVANY CHRISTOPHER A (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200230187-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | MCELVANY CHRISTOPHER A (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200069649-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -) ANALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2020-03-05 | — | — | US | disclosed |
| US-10456435-B2 | Topical antiviral formulations and methods of using the same | MCELVANY, Christopher A. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3551182-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2019-10-16 | — | — | EP | disclosed |
| US-20180207213-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | MCELVANY, CHRISTOPHER | 2018-07-26 | — | — | US | disclosed |
| WO-2018106108-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | KEPPEL HESSELING, Jan Marius (NL) | 2018-06-14 | — | — | WO | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| WO-2017011785-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | NATIONAL CONCESSIONS GROUP INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-20150190411-A1 | ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190411-A1 | ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | RESILIO COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| CN-102333777-B | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2014-06-25 | — | — | CN | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8618286-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-12-31 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| CN-101815713-B | Polycyclic compounds | EISAI R&D MAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| EP-2010527-B1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2013-08-14 | — | — | EP | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-8486374-B2 | Alcohol-free drug or cosmetics carrier mixture of water, hydrophobic solvent, surfactant and gelling agent; oil in water emulsions | FOAMIX LTD. (IL) | 2013-07-16 | — | — | US | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| EP-2181992-B1 | POLYCYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2559693-A1 | Polycyclic compound | Eisai R&D Management Co., Ltd. (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| CN-102333777-A | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2012-01-25 | — | — | CN | disclosed |
| EP-2401276-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-7935815-B2 | Imidazoyl pyridine compounds and salts thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7919510-B2 | treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain; selectively inhibits neuronal nitric oxide synthase (nNOS) over endothelial nitric oxide synthase (eNOS) and/or inducible nitric oxide synthase (iNOS) | NEURAXON, INC (CA) | 2011-04-05 | — | — | US | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010098495-A1 | IMIDAZOLYLPYRAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098488-A1 | ARYL IMIDAZOLE COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20100075926-A1 | ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-25 | — | — | US | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
| EP-2139886-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2010-01-06 | — | — | EP | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090163451-A1 | METHODS FOR TREATING VISCERAL PAIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-12-04 | — | — | US | disclosed |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-11-27 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | NEURAXON, INC (CA) | 2008-09-04 | — | — | US | disclosed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD | 2008-03-13 | — | — | US | disclosed |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040097562-A1 | Method for treating tension-type headache | HEAD EXPLORER APS (DK) | 2004-05-20 | — | — | US | disclosed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-5670684-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5576435-A | Process and intermediates for the preparation of excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| US-5470978-A | Process and intermediates for the preparation of excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0618197-A1 | Synthesis of CIS-decahydroisoquinoline-3-carboxylic acids | ELI LILLY AND COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0618196-A1 | Stereocontrolled synthesis of cis-bicyclic compounds | ELI LILLY AND COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0599518-A1 | Process and intermediates for the preparation of excitatory amino acide receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0599518-A1 | Process and intermediates for the preparation of excitatory amino acide receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (34 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | MEN1 1880/4885KMT2A 183/4885KDM4E 579/4885 |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | MEN1 4291/4885KMT2A 2758/4885KDM4E 2340/4885 |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | SLC6A2, AANAT, NOS3 | MEN1 2046/4885KMT2A 3105/4885KDM4E 2475/4885 |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | MEN1 936/4885KMT2A 1839/4885KDM4E 362/4885 |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | MEN1 3810/4885KMT2A 2332/4885KDM4E 2379/4885 |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | MEN1 424/4885KMT2A 1666/4885KDM4E 4536/4885 |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | SSTR2, SSTR3, LPXN | MEN1 1005/4885KMT2A 3672/4885KDM4E 4521/4885 |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | MEN1 4291/4885KMT2A 2758/4885KDM4E 2340/4885 |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | MEN1 3527/4885KMT2A 4757/4885KDM4E 4165/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | MEN1 4095/4885KMT2A 4685/4885KDM4E 4403/4885 |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | MEN1 3488/4885KMT2A 4543/4885KDM4E 3942/4885 |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | MEN1 3810/4885KMT2A 2332/4885KDM4E 2379/4885 |
| US-20100075926-A1 | ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL | GRIK5, HDAC11, GRIK1 | MEN1 3148/4885KMT2A 1179/4885KDM4E 826/4885 |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | NFATC1, TRAF6, UACA | MEN1 3021/4885KMT2A 3968/4885KDM4E 3946/4885 |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | BDNF, BACE1, GAP43 | MEN1 2307/4885KMT2A 3851/4885KDM4E 4049/4885 |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | MEN1 387/4885KMT2A 3881/4885KDM4E 3198/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | MEN1 947/4885KMT2A 2241/4885KDM4E 3909/4885 |
| US-20150190411-A1 | ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL | GRIK5, HDAC11, GRIK1 | MEN1 3160/4885KMT2A 1184/4885KDM4E 833/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | MEN1 3810/4885KMT2A 2332/4885KDM4E 2379/4885 |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | MEN1 3189/4885KMT2A 4563/4885KDM4E 4507/4885 |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | MEN1 3488/4885KMT2A 4543/4885KDM4E 3942/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | MEN1 4616/4885KMT2A 2478/4885KDM4E 3376/4885 |
| US-20040097562-A1 | Method for treating tension-type headache | GRIN3A, GRIN2A, GRIK4 | MEN1 859/4885KMT2A 40/4885KDM4E 479/4885 |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | GRIN2A, GRIN2B, GRIN3A | MEN1 4256/4885KMT2A 640/4885KDM4E 2158/4885 |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | MEN1 2707/4885KMT2A 620/4885KDM4E 1592/4885 |
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | OPRM1, NOS1, OPRK1 | MEN1 3188/4885KMT2A 1831/4885KDM4E 1942/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | MEN1 531/4885KMT2A 2179/4885KDM4E 4155/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | MEN1 3810/4885KMT2A 2332/4885KDM4E 2379/4885 |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | MEN1 3021/4885KMT2A 3968/4885KDM4E 3946/4885 |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS1, NOS2, NOS3 | MEN1 3486/4885KMT2A 2245/4885KDM4E 1823/4885 |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NOS1, NOS3, NOS2 | MEN1 2669/4885KMT2A 3297/4885KDM4E 2482/4885 |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | TPH1, NOS1, IDO1 | MEN1 3234/4885KMT2A 2112/4885KDM4E 2304/4885 |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | MEN1 4291/4885KMT2A 2758/4885KDM4E 2340/4885 |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | LIPA, PHOSPHO1, MYO1G | MEN1 3419/4885KMT2A 4572/4885KDM4E 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.